ISNES, Belgium, Dec. 5, 2017 /PRNewswire/ -- VolitionRx
Limited (NYSE American: VNRX) today announced that its
Executive Vice President, Scott
Powell, is scheduled to attend two conferences in
December.
During the conferences, management will outline Volition's
business, clinical, regulatory and operational milestones, as well
as the Company's recently announced two large clinical trials in
colorectal cancer at the University of
Copenhagen, Denmark, expected to be completed in the first
half of 2018.
Details of the conferences are as follows:
|
Conference:
|
LD Micro Conference
Main Event X
|
|
Date:
|
Wednesday, December
6, 2017
|
|
Time:
|
11:00 a.m.
PST
|
|
Location:
|
Luxe Sunset Hotel,
Los Angeles, CA
|
|
|
|
|
Conference:
|
Benchmark Company,
LLC Micro Cap Discovery One-on-One Conference
|
|
Date:
|
Thursday, December
14, 2017
|
|
Location:
|
Palmer House Hilton,
Chicago, IL
|
Persons attending any of the above-referenced conferences who
would like to schedule a 1-on-1 meeting with Volition management
during such conference may do so by contacting Joseph Green of Edison Advisors at
JGreen@edisongroup.com or Scott
Powell, Executive Vice President, at
S.Powell@volitionrx.com.
About Volition
Volition is a multi-national life sciences company developing
simple, easy to use blood-based cancer tests to accurately diagnose
a range of cancers. The tests are based on the science of
Nucleosomics®, which is the practice of identifying and
measuring nucleosomes in the bloodstream or other bodily fluid - an
indication that disease is present.
As cancer screening programs become more widespread, Volition's
products aim to help to diagnose a range of cancers quickly,
simply, accurately and cost effectively. Early diagnosis has the
potential to not only prolong the life of patients, but also to
improve their quality of life.
Volition's research and development activities are currently
centered in Belgium, with
additional offices in London,
Texas and Singapore, as the
company focuses on bringing its diagnostic products to market first
in Europe, then in the U.S. and
ultimately, worldwide.
For more information about Volition, visit Volition's website
(http://www.volitionrx.com) or connect with us via:
Twitter: https://twitter.com/volitionrx
LinkedIn:
https://www.linkedin.com/company/volitionrx
Facebook: https://www.facebook.com/VolitionRx/
YouTube: https://www.youtube.com/user/VolitionRx
The contents found at Volition's website address, Twitter,
LinkedIn, Facebook, and YouTube are not incorporated by reference
into this document and should not be considered part of this
document. The addresses for Volition's website, Twitter,
LinkedIn, Facebook, and YouTube are included in this document as
inactive textual references only.
Media / Investor Contacts
Louise Day,
Volition
L.day@volitionrx.com
+44 (0)7557
774620
|
Scott Powell,
Volition
S.powell@volitionrx.com
+1 (646) 650
1351
|
Joseph Green,
Edison Advisors
jgreen@edisongroup.com
+1 (646) 653
7030
|
Rachel Carroll,
Edison Advisors
rcarroll@edisongroup.com
+44 (0)20 3077
5711
|
View original
content:http://www.prnewswire.com/news-releases/volitionrx-limited-to-attend-conferences-in-december-300566612.html
SOURCE VolitionRx Ltd